13F-HR filed by Squadron Capital Management LLC
Squadron Capital Management LLC filed this 13F-HR for the quarter ended 2026-09-30, accepted by EDGAR 2026-11-16 21:33:40 UTC, with 45 holding rows worth $398,466,273.
- Accession
- 0002050709-26-000036
- Filer
- CIK 2050709
- Filed
- 2026-11-16
- Accepted by EDGAR
- Ingested
- Source
- EDGAR live feed
13F report for Q3 2026
A holdings report, 45 entries on the cover page, a total value of $398,466,273 stated on the cover page (in dollars after the unit check, H1), rows summing to $398,466,273 with VALUE read as dollars as filed, 13F file number 028-26573. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| KODIAK SCIENCES INC | 50015M109 | COM | 420,000 | $39,816,000 | dollars as filed | |
| C4 THERAPEUTICS INC | 12529R107 | COM STK | 9,318,683 | $31,031,214 | dollars as filed | |
| COGENT BIOSCIENCES INC | 19240Q201 | COM | 915,000 | $29,298,300 | dollars as filed | |
| KODIAK SCIENCES INC | 50015M109 | COM | 270,000 | $25,596,000 | dollars as filed | call |
| SILENCE THERAPEUTICS PLC | 82686Q101 | ADS | 2,085,000 | $22,789,050 | dollars as filed | |
| ZENTALIS PHARMACEUTICALS INC | 98943L107 | COMMON STOCK | 6,827,905 | $18,913,297 | dollars as filed | |
| EDGEWISE THERAPEUTICS INC | 28036F105 | COM | 425,000 | $17,255,000 | dollars as filed | |
| RELAY THERAPEUTICS INC COM | 75943R102 | Stock | 785,000 | $14,169,250 | dollars as filed | |
| ORIC PHARMACEUTICALS INC | 68622P109 | COM | 1,000,000 | $13,470,000 | dollars as filed | |
| RELMADA THERAPEUTICS INC | 75955J402 | COMMON STOCK | 3,500,000 | $13,195,000 | dollars as filed | |
| DEFINIUM THERAPEUTICS INC | 24477V105 | COM SHS | 340,000 | $12,940,400 | dollars as filed | |
| PHARVARIS NV | N69605108 | COMMON STOCK | 400,000 | $12,688,000 | dollars as filed | |
| Adlai Nortye | 00704R109 | SPONSORED ADS | 764,876 | $12,238,016 | dollars as filed | |
| VERA THERAPEUTICS INC | 92337R101 | COMMON STOCK | 305,000 | $9,848,450 | dollars as filed | |
| INVENTIVA SA | 46124U107 | ADS | 2,400,000 | $8,856,000 | dollars as filed | |
| DISC MEDICINE INC COM | 254604101 | Stock | 134,500 | $8,804,370 | dollars as filed | call |
| COGENT BIOSCIENCES INC | 19240Q201 | COM | 265,000 | $8,485,300 | dollars as filed | call |
| AVALO THERAPEUTICS INC | 05338F306 | COMMON STOCK | 450,000 | $6,898,500 | dollars as filed | |
| ACLARIS THERAPEUTICS INC COM | 00461U105 | Stock | 1,200,000 | $6,312,000 | dollars as filed | |
| REZOLUTE INC | 76200L309 | COMMON STOCK | 1,323,500 | $5,479,290 | dollars as filed | call |
| ASSEMBLY BIOSCIENCES INC | 045396207 | COMMON STOCK | 225,000 | $5,285,250 | dollars as filed | |
| ADAGENE INC | 005329107 | CMN | 1,616,618 | $5,173,178 | dollars as filed | |
| CRESCENT BIOPHARMA INC | G2545C104 | COMMON STOCK | 350,000 | $5,106,500 | dollars as filed | |
| Yarrow Bioscience, Inc. | 92941V407 | Common Stock, $0.0001 par value | 225,000 | $5,067,000 | dollars as filed | |
| ZURA BIO LTD | G9TY5A101 | COMMON STOCK | 1,200,000 | $4,992,000 | dollars as filed | |
| TCGX ACQUISITION CORP | G8708J109 | COM | 370,220 | $4,631,452 | dollars as filed | |
| CONTINEUM THERAPEUTICS INC CL A | 21217B100 | Stock | 323,570 | $4,342,309 | dollars as filed | |
| ARRIVENT BIOPHARMA INC | 04272N102 | COM | 142,500 | $4,314,900 | dollars as filed | call |
| INHIBIKASE THERAPEUTICS INC | 45719W205 | COMMON STOCK | 2,000,000 | $4,110,000 | dollars as filed | |
| PALISADE BIO INC | 696389402 | COMMON STOCK | 3,000,000 | $4,050,000 | dollars as filed | |
| TANGO THERAPEUTICS INC | 87583X109 | COM | 150,000 | $3,742,500 | dollars as filed | |
| JANUX THERAPEUTICS INC | 47103J105 | COM | 215,000 | $3,715,200 | dollars as filed | |
| SAVARA INC | 805111101 | COM | 675,000 | $3,483,000 | dollars as filed | |
| CONTINEUM THERAPEUTICS INC CL A | 21217B100 | Stock | 225,000 | $3,019,500 | dollars as filed | call |
| QUINCE THERAPEUTICS INC COM | 22053A305 | Stock | 90,000 | $2,790,900 | dollars as filed | |
| JATT III ACQUISITION CORP | G5080G109 | COM | 250,000 | $2,755,000 | dollars as filed | |
| SCYNEXIS INC | 811292309 | COM | 515,045 | $2,544,322 | dollars as filed | |
| SILENCE THERAPEUTICS PLC | 82686Q101 | ADS | 180,000 | $1,967,400 | dollars as filed | call |
| ALX ONCOLOGY HOLDINGS INC | 00166B105 | COMMON STOCK | 1,400,000 | $1,946,000 | dollars as filed | |
| LIPOCINE INC NEW | 53630X203 | COM NEW | 810,000 | $1,782,000 | dollars as filed | |
| BIOAGE LABS INC COM | 09077V100 | Stock | 250,000 | $1,772,500 | dollars as filed | call |
| PEPGEN INC COM | 713317105 | Stock | 600,000 | $1,452,000 | dollars as filed | |
| C4 THERAPEUTICS INC | 12529R107 | COM STK | 400,000 | $1,332,000 | dollars as filed | call |
| JATT II ACQUISITION CORP | G50765109 | ORD SHS | 65,000 | $730,925 | dollars as filed | |
| ZENTALIS PHARMACEUTICALS INC | 98943L107 | COMMON STOCK | 100,000 | $277,000 | dollars as filed | call |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0002050709-26-000036 | this filing | 2026-11-16 |